Cart
sales@molnova.com
p38 MAP Kinase Inhibitor Ⅵ
CAS No. 421578-46-3
p38 MAP Kinase Inhibitor Ⅵ( —— )
Catalog No. M36102 CAS No. 421578-46-3
p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 117 | In Stock |
|
| 5MG | 180 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 450 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 872 | In Stock |
|
| 500MG | 1737 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep38 MAP Kinase Inhibitor Ⅵ
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
-
Descriptionp38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24%.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number421578-46-3
-
Formula Weight332.42
-
Molecular FormulaC16H13FN2OS2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C(C)C2=C(S1)N=CN=C2SCC(=O)C1=CC=C(F)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cheeseright TJ, et al. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. J Med Chem. 2009 Jul 23;52(14):4200-9.?
molnova catalog
related products
-
RV01
RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity.
-
MW-150
MW-150 (MW01-18-150 SRM) is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM.
-
PH797804
PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
